Zydus’ biopharma arm acquires global proprietary rights for Progeria treatment
Saturday, 4 May 2024
Sentynl, under Zydus Lifesciences, acquired global rights for Zokinvy, the first FDA-approved Progeria treatment. An acquisition milestone in expanding the rare disease medicines portfolio, focusing on supporting patients.
|
||||
You Might Like |
||||
